Prospects of Melatonin as Adjuvant Therapy in Schizophrenic Patients: A Bibliometric Analysis Wahyuni1*, Satiawardana2, Herdaetha3, Kusuma 4 and Pramono5
1 Department of Psychiatry, Faculty of Medicine, Universitas Sebelas Maret, Indonesia
2Library, Universitas Sebelas Maret, Indonesia
3Department of Psychiatry, dr. Arif Zainudin Mental Hospital, Indonesia
4Department of Psychiatry, Faculty of Medicine, Universitas Sebelas Maret, Indonesia
5Department of Electrical Engineering, Faculty of Engineering, Universitas Sebelas Maret, Indonesia
Abstract
Schizophrenia is a severe mental disorder with a high recurrence rate. Schizophrenia sufferers experience persistent symptoms, interfering with their daily functions, which lead to decreased productivity. Various attempts have been made to improve clinical symptoms, one of them being providing additional therapies such as antioxidants, anti-inflammatory, and psychotherapy. As an adjuvant therapy, melatonin can play a role in attenuating pro-inflammatory cytokines and other inflammatory mediators and act as a free radical scavenger that protects from oxidative damage. This study was conducted to obtain an overview of the development of additional therapy research in schizophrenia patients and to see the prospects of melatonin being studied as an adjunct therapy. The data were taken from Scopus-indexed articles between 2003 and 2022. We analyzed these data bibliometrically using Vosviewer. We obtained 521 Scopus-indexed articles, in which VOSviewer visualization clustered them into 11 clusters relating to additional therapy for schizophrenia. Visualization results also revealed that studies on melatonin as adjuvant therapy for schizophrenia were still limited. In conclusion, the use of melatonin as adjuvant therapy for schizophrenic patients is prospective to be developed
